(VIANEWS) – TOUR EIFFEL (EIFF.PA), GALIMMO (GALIM.PA), SANOFI (SAN.PA) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio so far. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. TOUR EIFFEL (EIFF.PA)
625% Payout Ratio
Société de la Tour Eiffel is an integrated property company with EUR 1.8 bn in assets and a powerful service culture. This agile company operates in various asset classes, including offices, urban logistics, managed residential and retail, in Greater Paris and other major French metropolitan areas. An active player throughout the property cycle, it assists its tenants – companies of all sizes and sectors – through high-standard direct management of its properties. Société de la Tour Eiffel conducts a pro-active and transversal CSR policy that is an integral part of its strategic orientations. Société de la Tour Eiffel is listed on Euronext Paris (B board) – ISIN code: FR0000036816 – Reuters: TEIF.PA – Bloomberg: EIFF.FP – Member of the IEIF Foncières and IEIF Immobilier France indices.
Earnings Per Share
As for profitability, TOUR EIFFEL has a trailing twelve months EPS of €-0.65.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.54%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 13, 2023, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 5.84%.
Volume
Today’s last reported volume for TOUR EIFFEL is 1204 which is 23.06% below its average volume of 1565.
Yearly Top and Bottom Value
TOUR EIFFEL’s stock is valued at €13.05 at 21:10 EST, way below its 52-week high of €22.30 and above its 52-week low of €12.40.
More news about TOUR EIFFEL.
2. GALIMMO (GALIM.PA)
124.14% Payout Ratio
Galimmo SCA operates as a real estate company in Europe. As of December 31, 2021, it owned and managed 52 shopping malls. Galimmo SCA was formerly known as C&Co SCA and changed its name to Galimmo SCA in September 2016. The company was incorporated in 1902 and is headquartered in Paris, France. Galimmo SCA is a subsidiary of Galimmo Real Estate.
Earnings Per Share
As for profitability, GALIMMO has a trailing twelve months EPS of €0.29.
PE Ratio
GALIMMO has a trailing twelve months price to earnings ratio of 52.41. Meaning, the purchaser of the share is investing €52.41 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.01%.
More news about GALIMMO.
3. SANOFI (SAN.PA)
49.31% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €7.22.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 11.96. Meaning, the purchaser of the share is investing €11.96 for every euro of annual earnings.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 10.1% and positive 1.2% for the next.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €86.33 at 21:10 EST, way under its 52-week high of €105.18 and higher than its 52-week low of €80.60.
More news about SANOFI.
4. WDP (WDP.BR)
47.31% Payout Ratio
WDP develops and invests in logistics real estate (storage spaces and offices). WDP has more than 7 million m² of properties in its portfolio. This international portfolio of semi-industrial and logistics buildings is spread over approximately 300 sites at logistics hubs for storage and distribution in Belgium, the Netherlands, France, Luxembourg, Germany and Romania.
Earnings Per Share
As for profitability, WDP has a trailing twelve months EPS of €-0.46.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2%, now sitting on 385.1M for the twelve trailing months.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 27, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 4.01%.
More news about WDP.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1’s stock is considered to be overbought (>=80).
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.
More news about 1.
